AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05357846
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22
Trial: NCT06729307
Drug: Oral ondansetron and dyclonine hydrochloride mucilage
RxNorm normalized name: Dyclonine Hydrochloride
DrugBank: Dyclonine (DB00645)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take 8 mg oral ondansetron 2 hours prior to EGD process in addition to dyclonine hydrochloride mucilage to be gurgled 15 minutes prior to EGD process.
Trial: NCT06729307
Drug: Dyclonine hydrochloride mucilage
RxNorm normalized name: Dyclonine Hydrochloride
DrugBank: Dyclonine (DB00645)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to gurgle 10 mL of dyclonine chloride mucilage (0.01 g/mL) and gurgle for 1 minute 15 minutes prior to endoscopic process.
Trial: NCT06728345
Drug: Rimegepant
RxNorm normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Female migraine patients take Rimegepant (75mg QOD) as their regular prophylactic treatment of migraine for 12 weeks
Trial: NCT06727617
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of 300 mg, administered every 3 weeks as one cycle, on the first day of each cycle, with a maximum treatment duration of 2 years (up to 35 treatment cycles)
Trial: NCT05814757
Drug: OTX-DED
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.3mg dexamethasone ophthalmic insert
Trial: NCT05116917
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg/kg (up to 240 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle
Trial: NCT05116917
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 mg/kg will be given on day 1 cycle 1 (± 3 days) and once more after 6 weeks
Trial: NCT04818944
Drug: Tirofiban Hydrochloride
RxNorm normalized name: Tirofiban Hydrochloride
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tirofiban Hydrochloride will be dosed for 24 hours post MT via continuous IV
Trial: NCT06465472
Drug: Stiripentol Oral Capsule
RxNorm normalized name: stiripentol Oral Capsule
DrugBank: Stiripentol (DB09118)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The target dose of stiripentol will be 50 mg/kg/day with a maximum dose of 3,000 mg/day. Patients allocated to the Stiripentol group will receive this treatment during the first 6 months, and in continuation up to 12 months.
Trial: NCT04754061
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 (week 1): all enrolled participants will take a single 1mg oral dose of psilocybin once per day on Monday and Thursday. If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 2 for week 2.~Phase 2: The participant will take a single 1mg oral dose of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 3 for week 3.~Phase 3: The participant will take two 1mg oral doses (2mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 4 for week 4.~Phase 4 (maximum allowable dose): The participant will take three 1mg oral doses (3mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday).
Trial: NCT05633433
Drug: Azvudine
RxNorm normalized name: Azvudine
DrugBank: Azvudine (DB16407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azvudine is a novel nucleoside reverse transcriptase inhibitor.
Trial: NCT05786547
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Per package dosing, tablet taken orally
Trial: NCT05442060
Drug: Erlotinib (150 mg daily)
RxNorm normalized name: erlotinib 150 MG
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).
Trial: NCT04797650
Drug: CTP-543
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Administered as tablets.
Trial: NCT05175781
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: is a sympatholytic drug that acts as an agonist of α2-adrenergic receptors in certain parts of the brain.
Trial: NCT05175781
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine is an NMDA receptor antagoni
Trial: NCT05550636
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1015550
Trial: NCT05550636
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam
Trial: NCT05412004
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02660255
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Formulation: 100mg/ml CBD (Epidiolex) Solution
Trial: NCT04644029
Drug: Islatravir
RxNorm normalized name: Islatravir
DrugBank: Islatravir (DB15653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 60 mg tablet administered once monthly during Part 1.
Trial: NCT04192019
Drug: Micro-glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of 80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
Trial: NCT04192019
Drug: Mini-glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of 150 µg (mini-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
Trial: NCT05068141
Drug: SG001
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg, i.v., q2w
Trial: NCT05068141
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel for Injection (Albumin Bound), 100 mg/m\^2, i.v., D1, D8, D15 of every 4-week cycle
Trial: NCT05859217
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral once per day, Days 1 - 21 every 21 days
Trial: NCT05859217
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) once every 21 days
Trial: NCT05156684
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two trental tablets daily
Trial: NCT00000732
Drug: Sulfamethoxazole-Trimethoprim
RxNorm normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000732
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05656170
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group will receive bupivacaine injection guided by ultrasound at the location of the stellate ganglion.
Trial: NCT05656170
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group will receive a normal saline injection guided by ultrasound at the location of the stellate ganglion.
Trial: NCT06470061
Drug: Resveratrol, Quercetin, and Curcumin (RQC)
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg Curcumin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~334 mg Resveratrol/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~60 mg Quercetin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)
Trial: NCT06470061
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg Curcumin/day, taken twice daily for 7 days preceding each study visit (baseline and months 3, 6, 12, 18, and 24 for a total of 42 non-consecutive days over 24 months.
Trial: NCT04318847
Drug: Ondansetron 4 MG
RxNorm normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of ondansetron 4 mg or 8 mg according to weight
Trial: NCT05190627
Drug: Loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine 10mg/day added to rapamycin for 12 months
Trial: NCT05033431
Drug: Brazikumab
RxNorm normalized name: Brazikumab
DrugBank: Brazikumab (DB16115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV or SC injection of brazikumab as per the group they are assigned.
Trial: NCT04925557
Drug: Mayzent
RxNorm normalized name: Mayzent
DrugBank: Siponimod (DB12371)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PET imaging to evaluate the effects of Mayzent on the microglia of the brain.
Trial: NCT04925557
Drug: Ocrevus
RxNorm normalized name: Ocrevus
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PET imaging to evaluate the effects of Ocrevus on the microglia of the brain.
Trial: NCT04282174
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Thiotepa: 5mg/kg/day IV over approximately 4 hr. daily x 2 (Day -5 and Day -4). If scheduling of transplant harvests requires, the dose of Thiotepa may be administered as a single dose of 10mg/kg/day x 1.
Trial: NCT04282174
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified
Trial: NCT04282174
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 70mg/m2/day x 2 days IV over 30 minutes. Dose should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight per MCI standard of care guidelines. Melphalan will be administered on Days - 7 and -6 for multiple myeloma patients.
Trial: NCT04282174
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25mg/m2/days x 5 days IV over 30 minutes. Fludarabine may be adjusted in the case of renal toxicity.~In select cases in which the peripheral blood stem cells must be harvested a day later than requested due to a scheduling issue with the donor or Stem Cell Processing Laboratory.
Trial: NCT06258850
Drug: Calcifediol Oral Capsule
RxNorm normalized name: calcifediol Oral Capsule
DrugBank: Calcifediol (DB00146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One Hydroferol® soft capsule (0.266 mg) will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
Trial: NCT06074029
Drug: Immune Checkpoint Inhibitors
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab
Trial: NCT05401565
Drug: Balovaptan
RxNorm normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention of oral administration of 10mg balovaptan QD for 12 weeks followed by two weeks of follow-up period
Trial: NCT05603013
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine Tartrate Oral
Trial: NCT05603013
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF subcutaneous injection
Trial: NCT05603013
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 subcutaneous injection
Trial: NCT06452498
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin Hydrochloride encapsulated immediate-release tablet of 500 mg, backfilled with cellulose.
Trial: NCT05650203
Drug: JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006
RxNorm normalized name: Vitamin A and D in combination
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. JS009 as Monotherapy in first cycle of dose escalation and as the triple combination therapy will be administered in subsequent cycles：JS009,18mg/60mg/180mg/600mg/1200mg, JS006, fixed dose 600mg, Toripalimab injection fixed dose 240mg,IV infusion, every 3 weeks (q3w).~2. Triple combination therapy in dose expansion：JS009, 1 or 2 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w).~3. Triple combination therapy in indication expansion：JS009, 1 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w).
Trial: NCT05571111
Drug: FE 999302
RxNorm normalized name: Fe
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection as a single dose. 3 different doses
Trial: NCT05571111
Drug: Ovitrelle
DrugBank: Choriogonadotropin alfa (DB00097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection as a single dose. 250 µg (0.5 mL)
Trial: NCT05571111
Drug: Novarel
RxNorm normalized name: Novarel
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection as a single dose. 10,000 IU (1 mL)
Trial: NCT04298684
Drug: METFORMIN
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 1, the subjects will receive metformin at the initial dose of 500mg x 2 / day, which will be increased weekly to 500mgx3 / day and then 1gx2 / day in order to obtain the minimum effective dose on glycemic control. In case of intolerance, the tolerated and effective dose will be taken back provided an effective glycemic control.~A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced.
Trial: NCT04298684
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 2, sitagliptin will be prescribed at 100mg / day. A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced.
Trial: NCT06319027
Drug: Gadolinium-Chelate
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive gadolinium-based contrast agent
Trial: NCT04720248
Drug: Metamizole
RxNorm normalized name: Metamizole
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive metamizole intraoperatively and throughout 48h postoperatively.
Trial: NCT01406535
Drug: Vardenafil
RxNorm normalized name: Vardenafil
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg vardenafil per os twice daily
Trial: NCT05405439
Drug: Abiraterone acetate tablets
RxNorm normalized name: Abiraterone Acetate Tablets
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone acetate tablet is an inhibitor of cytochrome P450 17（CYP17）
Trial: NCT05405439
Drug: prednisone acetate tablets
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone acetate tablet is a kind of glucocorticoids
Trial: NCT05020327
Drug: Graded Oral Amoxicillin Challenge
RxNorm normalized name: amoxicillin Oral Suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin at 45 mg/kg (maximum of 1000 mg) to be divided into two doses: 10 % initial dose and then 90% remaining dose - doses will be separated by 30 minute interval
Trial: NCT01418443
Drug: Torrent's Pantoprazole Sodium Delayed - Release Tablets
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04789408
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05803031
Drug: Melaleuca Alternifolia Oil
RxNorm normalized name: Melaleuca alternifolia oil
DrugBank: Tea tree oil (DB11218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea tree oil 5% gel (Sigma Aldrich® Steinheim, Germany) for local sub gingival application was prepared by the Department of Pharmaceutics, Faculty of Pharmacy.~The gelling agent; Carbopol 940 (1% w/v) was first soaked in distilled water for 2 h then TTO dissolved in an appropriate amount of propylene glycol was added to the Carbopol dispersion. Methyl paraben 0.2% w/v dissolved in preheated water was used as a preservative. The gel mixture was then magnetically stirred for 30 min. Finally, pH was adjusted using 1 N NaOH added dropwise with gentle stirring with a spatula until the desired pH value (6.5-7) was reached. The gel was sterilized by autoclaving at 110 °C for 20 min.
Trial: NCT03361852
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
Trial: NCT03361852
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy
Trial: NCT05808881
Drug: Nalmefene Hydrochloride Injection
RxNorm normalized name: nalmefene Injection
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
Trial: NCT06399679
Drug: Rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
Trial: NCT05808881
Drug: Naloxone Hydrochloride Injection
RxNorm normalized name: Naloxone Hydrochloride Injection
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
Trial: NCT06004752
Drug: Ciclosporin
RxNorm normalized name: Ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclosporine was taken orally at 3-5mg/kg bid was administered to maintain the trough concentration at 100-200 μg/ml
Trial: NCT06004752
Drug: Avatrombopag
RxNorm normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avatrombopag was administrated at 40 mg/d and increased by 20 mg/d during the biweekly follow-up if platelet was not 20 × 109/L higher than baseline. AVA dose was gradually reduced if PLT ≥ 150 × 109/L. The maximum dose was 60 mg/d, while the minimum was 20 mg/week.
Trial: NCT04871854
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patients treated with Tocilizumab for Covid-19 infection
Trial: NCT06019741
Drug: Rivaroxaban and aspirin 80
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rivaroxaban 2.5 mg twice daily orally added to aspirin 80 mg post coronary bypass surgery
Trial: NCT06019741
Drug: Aspirin 80
RxNorm normalized name: aspirin 80 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin 80 mg orally post coronary bypass surgery
Trial: NCT05530577
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide (subcutaneous)
Trial: NCT05519813
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Use Metformin for 3 months to treat PCOS